By Kelly Cloonan
Shares of BriaCell Therapeutics climbed after the company said its late stage breast cancer treatment outperformed leading antibody-drug conjugates for some patients in its Phase 2 study.
The stock rose 16% to $4.34 on Wednesday. Shares have declined 87% over the past 12 months.
The biotechnology company said its Bria-IMT plus check point inhibitors showed a 17.3-month survival rate for patients with hormone receptor-positive breast cancer, exceeding the 14.4 months of Trodelvy, the current ADC standard of care.
For patients with triple negative breast cancer, the survival data for the treatment was similar to that of Trodelvy but higher than that of chemotherapy, the company said.
Patients with hormone receptor-positive and triple negative breast cancer represent a significant proportion of the patient population, yet are the most difficult groups to treat, Chief Medical Officer Dr. Giuseppe Del Priore said.
The Phase 2 data shows Bria-IMT has the potential to provide an effective and well-tolerated therapeutic option for those patient groups, Del Priore said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 16, 2025 13:32 ET (17:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。